BioXcell BE0101熱銷(xiāo)品介紹：InVivoMab anti-mouse PD-L1 (B7-H1)

產(chǎn)品描述：

BioXcell InVivoMab anti-mouse PD-L1 (B7-H1)?10F.9G2單克隆抗體與小鼠PD-L1（也稱(chēng)為B7-H1或CD274）反應(yīng)。PD-L1是屬于Ig超家族的B7家族的I型跨膜蛋白，分子量為40kDa。PD-L1在T淋巴細(xì)胞、B淋巴細(xì)胞、NK細(xì)胞、樹(shù)突狀細(xì)胞以及IFNγ刺激的單核細(xì)胞、上皮細(xì)胞和內(nèi)皮細(xì)胞上表達(dá)。PD-L1與CD4和CD8胸腺細(xì)胞以及活化的T和B淋巴細(xì)胞和骨髓細(xì)胞上的受體PD-1結(jié)合。PD-L1與PD-1的結(jié)合導(dǎo)致抑制TCR介導(dǎo)的T細(xì)胞增殖和細(xì)胞因子產(chǎn)生。PD-L1被認(rèn)為在腫瘤免疫逃避中起著重要作用。誘導(dǎo)的PD-L1表達(dá)在許多腫瘤中很常見(jiàn)，并導(dǎo)致腫瘤細(xì)胞對(duì)CD8 T細(xì)胞介導(dǎo)的裂解的抗性增加。在黑色素瘤的小鼠模型中，可以通過(guò)用阻斷PD-L1和PD-1之間相互作用的抗體處理來(lái)暫時(shí)腫瘤生長(zhǎng)。BioXcell InVivoMab anti-mouse PD-L1 (B7-H1)?10F.9G2抗體已被證明可以阻斷PD-L1和PD-1之間以及PD-L1和B7-1之間的相互作用（CD80）。

欣博盛生物是Bioxcell國(guó)內(nèi)授權(quán)代理商，Bioxcell現(xiàn)貨庫(kù)存中心，如需購(gòu)買(mǎi)BE0101或Bioxcell其它產(chǎn)品，請(qǐng)聯(lián)系！

?

產(chǎn)品詳情：

產(chǎn)品名稱(chēng)? InVivoMAb anti-mouse PD-L1 (B7-H1)

產(chǎn)品貨號(hào)??BE0101

產(chǎn)品規(guī)格??1/5/25/50/100mg

反應(yīng)種屬??Mouse

克隆號(hào)??10F.9G2

同種型??Rat IgG2a, κ

免疫原??Mouse CD274

實(shí)驗(yàn)應(yīng)用

in vivo PD-L1 blockade

Immunofluorescence

Immunohistochemistry (frozen)

Flow cytometry

Western blot

產(chǎn)品形式??PBS, pH 6.5,Contains no stabilizers or preservatives

純度??>95%, Determined by SDS-PAGE

無(wú)菌處理??0.2 μm filtration

純化方式??Protein G

RRID??AB_10949073

分子量??150 kDa

保存條件??抗體原液保存在4°C，不能冷凍保存。

推薦同型對(duì)照

InVivoMAb rat IgG2b isotype control, anti-keyhole limpet hemocyanin（貨號(hào)BE0090）

推薦抗體稀釋液

InVivoPure pH 6.5 Dilution Buffer（貨號(hào)IP0065）

該產(chǎn)品自上市已被多篇SCI文獻(xiàn)引用，品質(zhì)有保證，以下是部分已發(fā)表的文獻(xiàn)引用：

體內(nèi)PD-L1信號(hào)阻斷(in vivo PD-L1 blockade)

1.?Grasselly, C., et al. (2018). 'The Antitumor Activity of Combinations of Cytotoxic Chemotherapy and Immune Checkpoint Inhibitors Is Model-Dependent' Front Immunol 9: 2100.

2.?Stathopoulou, C., et al. (2018). 'PD-1 Inhibitory Receptor Downregulates Asparaginyl Endopeptidase and Maintains Foxp3 Transcription Factor Stability in Induced Regulatory T Cells' Immunity 49(2): 247-263 e247. ?

3.?Jaworska, K., et al. (2015). 'Both PD-1 ligands protect the kidney from ischemia reperfusion injury' J Immunol 194(1): 325-333.

4.?Kim, J., et al. (2015). 'Memory programming in CD8(+) T-cell differentiation is intrinsic and is not determined by CD4 help' Nat Commun 6: 7994. ?

5.?Zander, R. A., et al. (2015). 'PD-1 Co-inhibitory and OX40 Co-stimulatory Crosstalk Regulates Helper T Cell Differentiation and Anti-Plasmodium Humoral Immunity' Cell Host Microbe 17(5): 628-641.

6.?Tkachev, V., et al. (2015). 'Programmed death-1 controls T cell survival by regulating oxidative metabolism' J Immunol 194(12): 5789-5800.

7.?Twyman-Saint Victor, C., et al. (2015). 'Radiation and dual checkpoint blockade activate non-redundant immune mechanisms in cancer' Nature 520(7547): 373-377.

體內(nèi)PD-L1阻斷，流式細(xì)胞術(shù)(in vivo PD-L1 blockade, Flow Cytometry)

1.?loulou, M., et al. (2016). 'Follicular regulatory T cells can be specific for the immunizing antigen and derive from naive T cells' Nat Commun 7: 10579.

2.?Ngiow, S. F., et al. (2015). 'A Threshold Level of Intratumor CD8+ T-cell PD1 Expression Dictates Therapeutic Response to Anti-PD1' Cancer Res 75(18): 3800-3811.

3.?Rutigliano, J. A., et al. (2014). 'Highly pathological influenza A virus infection is associated with augmented expression of PD-1 by functionally compromised virus-specific CD8+ T cells' J Virol 88(3): 1636-1651.

體內(nèi)PD-L1阻斷，免疫熒光(in vivo PD-L1 blockade, Immunofluorescence)

1.Willimsky, G., et al. (2013). 'Virus-induced hepatocellular carcinomas cause antigen-specific local tolerance' J Clin Invest 123(3): 1032-1043.

免疫組織化學(xué)（冷凍），免疫熒光(Immunohistochemistry (frozen), Immunofluorescence)

1.Riella, L. V., et al. (2011). 'Essential role of PDL1 expression on nonhematopoietic donor cells in acquired tolerance to vascularized cardiac allografts' Am J Transplant 11(4): 832-840.